Mark M. Zalupski
- Oncology top 0.2%
- Pancreatic and Hepatic Oncology Research 87
- Colorectal Cancer Treatments and Studies 34
- Cancer Treatment and Pharmacology 18
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 38
- Pulmonary and Respiratory Medicine top 0.5%
- Sarcoma Diagnosis and Treatment 27
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 21
- Gastroenterology top 2%
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 29
-
- Neuroendocrine Tumor Research Advances 27
- Co-authors
- Theodore S. LawrenceAnthony F. ShieldsLaurence H. BakerCornelius J. McGinnKent A. GriffithEdgar Ben‐JosefPhilip A. PhilipLance K. Heilbrun
- Journals
- Journal of Clinical Oncology (64 papers)JNCI Journal of the National Cancer Institute (2 papers)Cancer (12 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Mark M. Zalupski
192 papers receiving 6.8k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 4.9k
- Cancer Research 1.4k
- Pulmonary and Respiratory Medicine 2.4k
- Hepatology 376
- Gastroenterology 212
Countries citing papers authored by Mark M. Zalupski
This map shows the geographic impact of Mark M. Zalupski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Zalupski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Zalupski more than expected).
Fields of papers citing papers by Mark M. Zalupski
This network shows the impact of papers produced by Mark M. Zalupski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Zalupski. The network helps show where Mark M. Zalupski may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark M. Zalupski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 18 | |
| 5 | 2023 | 1 | |
| 6 | Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)breakdown → | 2022 | 125 |
| 7 | 2022 | 5 | |
| 8 | HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinomabreakdown → | 2017 | 365 |
| 9 | 2017 | 4 | |
| 10 | 2017 | 5 | |
| 11 | 2017 | 22 | |
| 12 | 2016 | 27 | |
| 13 | 2014 | 236 | |
| 14 | 2012 | 143 | |
| 15 | 2012 | 92 | |
| 16 | 2010 | 18 | |
| 17 | 2009 | 3 | |
| 18 | 2003 | 82 | |
| 19 | 1999 | 4 | |
| 20 | 1994 | 27 |
About Mark M. Zalupski
Mark M. Zalupski is a scholar working on Oncology, Hepatology and Cancer Research, having authored 197 papers that have together received 6.9k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (87 papers), Cancer Genomics and Diagnostics (38 papers), Colorectal Cancer Treatments and Studies (34 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (29 papers), Neuroendocrine Tumor Research Advances (27 papers), Sarcoma Diagnosis and Treatment (27 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers) and Cancer Treatment and Pharmacology (18 papers). The work is most often cited by research in Oncology (4.9k citations), Cancer Research (1.4k citations) and Pulmonary and Respiratory Medicine (2.4k citations). Mark M. Zalupski has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Theodore S. Lawrence, Anthony F. Shields, Laurence H. Baker, Cornelius J. McGinn, Kent A. Griffith, Edgar Ben‐Josef, Philip A. Philip, Lance K. Heilbrun, Vaibhav Sahai and Tanios Bekaii‐Saab. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.